-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
Monopar Therapeutics quarterly/annual General and Administrative Expense history and growth rate from Q1 2017 to Q3 2024.
- Monopar Therapeutics General and Administrative Expense for the quarter ending September 30, 2024 was $591K, a 21.2% decline year-over-year.
- Monopar Therapeutics General and Administrative Expense for the twelve months ending September 30, 2024 was $2.88M, a 8.81% decline year-over-year.
- Monopar Therapeutics annual General and Administrative Expense for 2023 was $3.23M, a 9.7% increase from 2022.
- Monopar Therapeutics annual General and Administrative Expense for 2022 was $2.95M, a 11.8% increase from 2021.
- Monopar Therapeutics annual General and Administrative Expense for 2021 was $2.63M, a 7.79% increase from 2020.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)